Total Clarity Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Total Clarity Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,085	Closed	-$245K	–	340
2025 Q1	$245K	Hold	6,085	–	–	0.08%	222
2024 Q4	$245K	Sell	6,085 -2,674	-31%	-$152K	0.08%	223
2024 Q3	$555K	Buy	8,759 +2,419	+38%	+$142K	0.18%	137
2024 Q2	$336K	Sell	6,340 -9,441	-60%	-$619K	0.12%	173
2024 Q1	$1.29M	Buy	+15,781	New	+$702K	0.45%	60
2023 Q3	–	Sell	-14,480	Closed	-$235K	–	239
2023 Q2	$235K	Sell	14,480 -9,170	-39%	-$192K	0.12%	187
2023 Q1	$394K	Buy	+23,650	New	+$244K	0.21%	109

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Total Clarity Wealth Management's VKTX Position: Q2 2025 in Review

Total Clarity Wealth Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 6,085 shares — an estimated $245K sold.

Total Clarity Wealth Management first reported a position in VKTX in Q1 2023 and held it in 7 quarters. The position peaked at $1.29M in Q1 2024. 392 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Total Clarity Wealth Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Total Clarity Wealth Management sold 6,085 Viking Therapeutics shares in Q2 2025, an estimated $245K.
Total Clarity Wealth Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 7 quarters.
Total Clarity Wealth Management's Viking Therapeutics position peaked at $1.29M in Q1 2024.
392 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Total Clarity Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.